Bernard-Soulier syndrome is a rare bleeding disorder that you are born with. It happens because the platelets do not stick well to damaged blood vessels. Platelets are tiny blood cells that start a blood clot when you get a cut. In BSS, platelets are fewer than normal and much larger than normal. Most importantly, they are missing or have poorly working parts of a protein “hook” on their surface called the GPIb-IX-V complex (also called the CD42 complex). This hook normally grabs von Willebrand factor (vWF), which is a glue-like protein that helps platelets attach to the vessel wall at the very start of clotting. When this hook is absent or faulty, platelets cannot attach well, so bleeding lasts longer and can be heavy. BSS is usually inherited in an autosomal recessive way. That means a child gets a faulty gene from both parents. The main genes are GP1BA, GP1BB, and GP9. There is also a very rare acquired form caused by an immune attack on the GPIb-IX-V complex. People with BSS often have nosebleeds, gum bleeding, easy bruising, and in women, heavy menstrual bleeding. Bleeding after dental work, surgery, or childbirth can be serious. Many people are diagnosed in childhood after easy bruising or nosebleeds. The platelet count is usually low to moderately low, the platelets look very large on a blood smear, and special function tests show a markedly reduced or absent response to the drug ristocetin, a classic laboratory clue for BSS.

Bernard–Soulier syndrome is a rare, inherited bleeding disorder where platelets are unusually large and low in number (macrothrombocytopenia) and cannot stick properly to damaged blood vessels, because the platelet surface receptor complex GPIb-IX-V is missing or not working. People bruise easily, have nosebleeds, gum bleeding, heavy menstrual bleeding, and can bleed more with surgery, dental work, or injury. BSS is usually autosomal recessive and caused by variants in GP1BA, GP1BB, or GP9. Diagnosis relies on blood smear (giant platelets), low platelet count, absent/markedly reduced ristocetin-induced aggregation, and specialized flow cytometry. Management focuses on preventing bleeding, local measures, antifibrinolytics, and—when needed—platelet transfusions (ideally HLA-matched); rFVIIa may be used off-label when platelets are not available or alloimmunization develops. ASH Publications+3NCBI+3Orpha+3

---

Other names

BSS is known by several other names in medical books and articles. These names talk about the same condition:

• Bernard-Soulier syndrome (BSS)

• Hemorrhagiparous thrombocytic dystrophy

• Giant platelet syndrome (Bernard-Soulier type)

• Congenital macrothrombocytopenia with platelet dysfunction

• Platelet glycoprotein Ib deficiency

• CD42 complex deficiency

• GPIb-IX-V complex deficiency

• Autosomal recessive giant platelet disorder (Bernard-Soulier)

---

Types

1. Classic, biallelic BSS
   This is the most common form. A person inherits faulty copies of a BSS gene from both parents. The GPIb-IX-V complex is absent or very reduced. Platelet count is low, platelets are very large, and bleeding can be moderate to severe.

2. Variant (qualitative) BSS
   Here the amount of the complex may be near normal, but the complex does not work well. The vWF “hook” is present but cannot bind effectively. Bleeding symptoms are similar, and lab tests show poor ristocetin response.

3. Monoallelic (heterozygous) BSS / “BSS-like” macrothrombocytopenia
   Some people with a single disease-causing variant can have large platelets, mild thrombocytopenia, and mild bleeding. This is milder than classic BSS but can still cause problems, especially with surgery or trauma.

4. Acquired BSS
   This is not inherited. The immune system makes antibodies against the GPIb-IX-V complex, or the complex is blocked by another disease (for example, some autoimmune conditions, certain lymphomas, or rarely after cardiac bypass). Bleeding resembles inherited BSS, but treatment focuses on the underlying immune problem.

5. Genotype-defined subtypes
   Doctors sometimes classify BSS by the specific gene affected: GP1BA-related, GP1BB-related, or GP9-related disease. Different variants can change how much of the complex is made, how stable it is, or how well it binds vWF, which can influence test results and bleeding severity.

---

Causes

Note: BSS itself is caused by gene changes or, rarely, an immune attack. Many items below are “aggravating factors” that worsen bleeding in someone who already has BSS.

1. Pathogenic variants in GP1BA
   Changes in this gene damage the GPIbα subunit. The subunit cannot bind vWF well. Adhesion fails at the first step of clotting.

2. Pathogenic variants in GP1BB
   This gene encodes GPIbβ. Faulty GPIbβ impairs assembly of the whole complex. Surface expression drops. Platelets cannot hook onto vWF.

3. Pathogenic variants in GP9
   This gene encodes GPIX. Without a healthy GPIX, the complex does not fold or traffic to the platelet surface. Platelet adhesion is poor.

4. Compound heterozygosity (two different harmful variants)
   Two different faulty variants, one from each parent, can combine to cause classic BSS. The complex level can be extremely low.

5. Homozygous null variants
   Two “stop” or “deletion” variants can wipe out production of a subunit. The complex is absent. Bleeding may be more severe.

6. Missense variants that disrupt vWF binding
   A single amino-acid change can weaken the exact contact point where GPIbα binds vWF. Function is reduced even if the complex is present.

7. Variants that destabilize the complex
   Some changes do not touch the binding site but make the complex unstable. It breaks down more easily and falls off the platelet surface.

8. Acquired autoantibodies to GPIb-IX-V
   In acquired BSS, antibodies coat or block the complex. The platelet cannot bind vWF. Thrombocytopenia may worsen due to immune clearance.

9. Thrombocytopenia from splenic sequestration
   In people with BSS, a large spleen can trap platelets. The count falls, and bleeding risk rises. The macroplatelets are more likely to be removed.

10. Antiplatelet drugs (e.g., aspirin, clopidogrel, NSAIDs)
    These medicines block platelet function. In BSS they can greatly worsen bleeding and should be avoided unless a specialist says otherwise.

11. Selective serotonin reuptake inhibitors (SSRIs)
    These antidepressants lower platelet serotonin stores, which help platelets work. They can slightly increase bleeding in BSS.

12. Alcohol use
    Alcohol can suppress platelet production and function. It also irritates the stomach lining and increases bleeding risk.

13. Viral infections
    Some infections temporarily lower platelet counts or affect function. During infection, BSS bleeding can flare.

14. Nutritional deficiencies (iron, folate, B12)
    Low iron causes anemia and worsens fatigue and bleeding tolerance. Folate and B12 help make blood cells; deficiency can lower counts.

15. Pregnancy-related changes
    Pregnancy can lower platelet counts in some people and increase bleeding at delivery. Careful planning reduces risk.

16. Surgery or dental extraction
    Tissue injury exposes many small vessels. With BSS, platelets cannot seal them well. Bleeding can be prolonged without a plan.

17. Trauma
    Even small hits can cause big bruises in BSS because platelets cannot stop bleeding quickly.

18. Uncontrolled high blood pressure
    High pressure in vessels can worsen nosebleeds and other mucosal bleeding in BSS.

19. Coexisting bleeding disorders (e.g., von Willebrand disease)
    If a person with BSS also has vWF problems, bleeding is even harder to control.

20. Anticoagulants and some herbal products
    Blood thinners (like warfarin, DOACs, heparin) and herbs such as ginkgo, garlic, or high-dose fish oil can increase bleeding in BSS.

---

Symptoms

1. Easy bruising
   Bruises appear after minor bumps or even without a clear cause. They can be large and take time to fade.

2. Frequent nosebleeds (epistaxis)
   Nosebleeds can be hard to stop because the nose has many small vessels and the platelets cannot stick well.

3. Gum bleeding
   Gums may bleed with brushing or flossing. Dental cleanings can trigger longer bleeding.

4. Prolonged bleeding from cuts
   Small cuts may ooze for a long time. A pressure bandage and careful care are often needed.

5. Heavy menstrual bleeding (menorrhagia)
   Periods can be long, heavy, and include clots. This can cause iron-deficiency anemia and tiredness.

6. Bleeding after dental work
   Tooth extraction or deep cleaning can cause prolonged bleeding without proper prevention.

7. Bleeding after surgery
   Operations can lead to oozing at the wound site and bleeding under the skin unless a plan is made before surgery.

8. Petechiae or purpura
   Tiny red or purple spots can appear under the skin from small vessel bleeding.

9. Bleeding from the gastrointestinal tract
   Some people have black stools or red blood from the rectum. This needs urgent medical review.

10. Blood in urine (hematuria)
    Red or brown urine can appear after minor trauma or infection. It should be evaluated.

11. Postpartum hemorrhage
    Bleeding after giving birth can be heavier and last longer in BSS. Planning with obstetrics and hematology lowers risk.

12. Anemia-related fatigue and shortness of breath
    Ongoing blood loss may lead to low hemoglobin. People feel tired, weak, or short of breath on exertion.

13. Prolonged bleeding after vaccinations or injections
    The needle site may ooze longer. Firm pressure for several minutes helps.

14. Bleeding after nose picking or blowing
    Fragile nasal vessels bleed easily in BSS. Gentle care and humidification can help.

15. Rare serious bleeding
    Serious events like bleeding into the brain or deep muscles are uncommon but can happen after major trauma or surgery.

---

Diagnostic tests

A) Physical exam (bedside observations)

1. General inspection for bruises and skin changes
   The doctor looks for many bruises in different stages of healing, petechiae, or large hematomas. This pattern supports a platelet-type bleeding problem rather than a clotting-factor problem.

2. Oral and nasal exam
   The doctor checks gums, tongue, and nasal lining for active bleeding, crusts, or fragile vessels. Mucosal bleeding points to a platelet adhesion defect like BSS.

3. Spleen size assessment
   The doctor gently feels the abdomen to check spleen size. An enlarged spleen can lower platelet counts and worsen BSS bleeding.

B) “Manual” or bedside tests / clinical tools

4. Standardized bleeding history score (e.g., ISTH-BAT)
   A structured questionnaire scores the severity and pattern of bleeding. A high score suggests a significant bleeding disorder and guides further tests.

5. Local pressure test at venipuncture sites
   Clinicians observe how long bleeding takes to stop after a blood draw with standard pressure. Prolonged oozing is common in platelet disorders.

6. Point-of-care platelet function screen (PFA-100/200 closure time)
   This device measures how fast platelets plug a small hole under flow. In BSS, closure time is often very prolonged because GPIb-vWF binding is impaired.

(Historical Ivy bleeding time is rarely used today due to poor accuracy and discomfort.)

C) Laboratory and pathological tests

7. Complete blood count (CBC) with platelet count and indices
   CBC shows low to moderately low platelet count and a high mean platelet volume (MPV). This pattern suggests macrothrombocytopenia, typical for BSS.

8. Peripheral blood smear (microscopy)
   A lab expert looks at blood under a microscope. Platelets look giant and fewer in number. This is a classic clue for BSS.

9. Light transmission aggregometry (LTA)
   This is the gold-standard function test. In BSS, aggregation to ADP, collagen, or epinephrine may be present, but response to ristocetin is absent or severely reduced because GPIb-vWF binding is defective.

10. Ristocetin-induced platelet agglutination (RIPA)
    RIPA specifically tests the platelet-vWF interaction. In BSS, agglutination is absent even at high ristocetin doses. This helps distinguish BSS from other disorders.

11. Von Willebrand factor panel (vWF antigen, activity, Factor VIII)
    These tests rule out von Willebrand disease (low vWF) and platelet-type vWD (a different disorder where platelets bind vWF too strongly). Normal vWF with absent ristocetin response supports BSS.

12. Flow cytometry for platelet surface glycoproteins (CD42a/CD42b)
    This test measures the amount of GPIb-IX-V on platelets. In BSS, CD42b (GPIbα) and related markers are reduced or absent. It is a strong confirmatory test.

13. Genetic testing of GP1BA, GP1BB, and GP9
    DNA testing finds the exact variant. It confirms the diagnosis, allows family counseling, and distinguishes classic from monoallelic forms.

14. Western blot or immunoblot for glycoprotein subunits
    Some labs check for the presence/size of the glycoprotein subunits. Absent or abnormal bands support BSS.

15. Testing for anti-GPIb antibodies (acquired BSS workup)
    If BSS starts later in life or after another illness, blood tests can look for antibodies against GPIb. A positive test supports acquired BSS.

16. Thromboelastography (TEG) or ROTEM
    Whole-blood clotting is monitored over time. In BSS there can be prolonged clot initiation and weak clot firmness in platelet-driven phases.

17. Iron studies (ferritin, transferrin saturation)
    Chronic mucosal bleeding can cause iron deficiency. Low ferritin supports iron-deficiency anemia that needs treatment.

18. Coagulation tests (PT/INR, aPTT)
    These are usually normal in BSS, which helps separate platelet disorders from clotting-factor deficiencies.

D) Electrodiagnostic tests

(There are no true nerve-or-muscle electrodiagnostic tests for BSS; here “electrodiagnostic” refers to instrumented hemostasis testing.)

19. Platelet impedance aggregometry
    This is another instrumented platelet test performed in whole blood. It often mirrors LTA findings, with poor ristocetin-mediated aggregation in BSS.

E) Imaging tests (to look for bleeding sites or complications)

20. Ultrasound/CT/MRI targeted to symptoms
    Imaging is not used to diagnose BSS itself, but it finds bleeding sources and complications. Examples include CT for suspected intracranial bleeding after trauma, ultrasound for pelvic causes of heavy periods, or endoscopy (camera test) for GI bleeding.

Non-pharmacological treatments (therapies & other measures)

1. Personalized bleeding avoidance plan
   Create a simple written plan: avoid contact sports; use protective gear; treat nasal dryness; keep nails short; and carry a bleeding-disorder card. Purpose: reduce everyday triggers of mucosal and soft-tissue bleeding. Mechanism: fewer minor traumas means fewer opportunities for platelets to be tested at vessel walls where GPIb-IX-V is needed. NCBI

2. Nasal moisture & compression for nosebleeds
   Use humidification/saline gel and firm nostril pinching for 10–15 minutes leaning forward. Purpose: stop epistaxis without drugs. Mechanism: moisture protects fragile mucosa; direct pressure tamponades small vessels so less platelet adhesion is required. NCBI

3. Local pressure, elevation, and ice for cuts
   Immediate firm pressure with a clean cloth, elevate the limb, and apply a cold pack. Purpose: quick home hemostasis. Mechanism: mechanical compression and vasoconstriction slow bleeding while the clot forms. NCBI

4. Dental prevention program
   Soft toothbrush, flossing technique, alcohol-free mouth rinses, and regular hygienist visits, plus dental work in a center familiar with bleeding disorders. Purpose: prevent gingival bleeding and plan care safely. Mechanism: good gum health reduces inflamed, fragile surfaces that bleed easily. NCBI

5. Menstrual management planning (non-drug measures)
   Track cycles; use high-absorbency pads, menstrual cups with caution, and iron-rich diet; coordinate with gynecology before procedures. Purpose: reduce impact of heavy menstrual bleeding (HMB). Mechanism: anticipatory care and safe products lower mucosal trauma. (Drug options appear later.) ACOG+1

6. Surgical and dental procedure protocols
   Advance notice to hematology; schedule procedures early day/early week; secure hemostasis; consider local measures like sutures and prolonged pressure. Purpose: reduce peri-procedural bleeding. Mechanism: meticulous local hemostasis compensates for defective platelet adhesion. ASH Publications

7. Bleeding first-aid kit at home
   Clean gauze, nose clips, ice packs, and your treatment plan. Purpose: act quickly when bleeding starts. Mechanism: early mechanical control narrows the window where platelets must adhere effectively. NCBI

8. Pregnancy & delivery plan
   Early multidisciplinary plan (hematology, obstetrics, anesthesia). Purpose: safe childbirth with minimal bleeding. Mechanism: anticipating delivery routes and hemostatic support reduces major hemorrhage risk in a platelet adhesion disorder. ASH Publications

9. Genetic counseling for families
   Offer counseling to understand inheritance, testing, and family planning options. Purpose: inform at-risk relatives and future parents. Mechanism: carrier and prenatal knowledge reduces unexpected bleeding risks in newborns and guides planning. Orpha

10. Medical alert identification
    Carry/wear an alert card/bracelet naming BSS, “no NSAIDs,” and emergency contacts. Purpose: faster, safer emergency care. Mechanism: clinicians apply correct hemostatic strategies promptly. NCBI

11. Safe exercise strategy
    Prefer low-impact activities (walking, swimming, cycling with helmet). Purpose: fitness without trauma. Mechanism: strengthens cardiovascular health while avoiding bruising/bleeding from high-impact sports. NCBI

12. Iron repletion through diet planning
    If you lose blood frequently, coordinate diet for iron (meat/legumes), folate, and B12 via foods first. Purpose: prevent iron-deficiency anemia from chronic bleeding. Mechanism: supports red cell production, improving energy and recovery. (Supplements appear later.) NCBI

13. Avoidance of platelet-impairing exposures
    Avoid over-the-counter NSAIDs (ibuprofen, naproxen), high-dose alcohol, and certain herbal products that worsen platelet function (e.g., ginkgo). Purpose: don’t add a second hit to already impaired platelets. Mechanism: prevents further inhibition of aggregation. ASH Publications

14. Mouth and gum care before orthodontics
    If braces or extractions are planned, optimize gum health and schedule in a center prepared for bleeding disorders. Purpose: reduce bleeding complications. Mechanism: healthier gingivae bleed less during manipulation. NCBI

15. Epistaxis clinic techniques (non-drug)
    For recurrent nosebleeds, ENT can advise humidification, emollients, and compression education; chemical cautery is considered separately under surgery. Purpose: reduce episodes. Mechanism: mucosal protection minimizes breaks in surface vessels. NCBI

16. School/workplace accommodations
    Simple accommodations (ready access to first-aid, avoiding heavy contact tasks). Purpose: safety and inclusion. Mechanism: reduces risk scenarios that provoke bleeding. NCBI

17. Vaccination planning for transfusion prevention
    Ensure hepatitis A/B vaccination if transfusions are anticipated. Purpose: lower infectious risks associated with blood exposure. Mechanism: immune protection in case blood products are needed. ASH Publications

18. Hematology center follow-up
    Regular review to update your plan, labs, and procedure letters. Purpose: early problem-solving. Mechanism: ongoing specialist care reduces emergency-only management. ASH Publications

19. Travel preparation
    Pack your plan, supplies, and identify a nearby hematology center; avoid high-risk adventure activities. Purpose: safe travel. Mechanism: readiness shortens time to control bleeding far from home. NCBI

20. Community and psychological support
    Join rare-disease/bleeding-disorder communities; consider counseling if anxiety about bleeding is high. Purpose: coping and adherence. Mechanism: support improves self-management and timely care-seeking. NCBI

---

Drug treatments

Note: Some are off-label in BSS but commonly used for hemostasis in inherited platelet disorders. Dosing must be individualized by your hematology team.

1. Tranexamic acid (oral)
   Class: Antifibrinolytic. Purpose: Reduce mucosal bleeding (e.g., nose, gums, menses). Typical dose/time: Adults often 1.3 g orally three times daily during bleeding days (menstrual label); duration tailored to site/severity. Mechanism: Blocks lysine binding sites on plasminogen, stabilizing fibrin clots so they don’t break down too fast. Side effects: Nausea, cramps; rare thrombosis risk; avoid in active intravascular clotting. Evidence: FDA-approved for cyclic heavy menstrual bleeding (LYSTEDA label). FDA Access Data+1

2. Tranexamic acid (IV)
   Class: Antifibrinolytic. Purpose: Procedural or acute bleeding control when oral route unsuitable. Dose/time: Common peri-operative regimens 10 mg/kg IV; repeat per clinical need. Mechanism: Same as oral; faster onset. Side effects: As above; monitor for thrombosis. Evidence: Widely used peri-operatively; aligns with ACOG guidance for acute abnormal uterine bleeding. Lippincott Journals

3. Aminocaproic acid (oral/IV)
   Class: Antifibrinolytic. Purpose: Alternative to tranexamic acid for mucosal bleeding and dental work. Dose/time: Oral loading 4–5 g, then 1 g hourly for 8 hours or until bleeding controlled; IV options exist. Mechanism: Competitively inhibits plasminogen activation to keep clots stable. Side effects: Hypotension with rapid IV use, myopathy with prolonged high doses, rare thrombosis. Evidence: FDA label for bleeding due to hyperfibrinolysis (AMICAR). FDA Access Data+1

4. Recombinant activated factor VII (rFVIIa; NovoSeven RT)
   Class: Recombinant coagulation factor (bypassing agent). Purpose: Rescue therapy for severe bleeds or surgery when platelets are unavailable or alloimmunization causes refractoriness. Dose/time: Dosing is individualized (e.g., 90 µg/kg IV; repeat per response). Mechanism: Directly activates factor X on the surface of activated platelets/tissue factor, generating thrombin to stabilize clot despite poor platelet adhesion. Side effects: Thromboembolic events, especially with risk factors. Evidence: FDA-approved for hemophilia with inhibitors and Glanzmann’s thrombasthenia with refractoriness; used off-label in BSS. U.S. Food and Drug Administration+1

5. Desmopressin (DDAVP)
   Class: Vasopressin analogue. Purpose: Sometimes used to reduce mucosal bleeding; benefit in BSS is variable. Dose/time: IV 0.3 µg/kg over 15–30 min or intranasal per label; strict fluid restriction to avoid hyponatremia. Mechanism: Releases endothelial vWF and factor VIII, improving platelet adhesion in some settings; effect in GPIb-deficient states may be limited. Side effects: Headache, flushing, hyponatremia (serious). Evidence: FDA labeling for other indications; used cautiously as adjunct in platelet function disorders. FDA Access Data+1

6. Topical fibrin sealant (e.g., fibrin glue during procedures)
   Class: Topical hemostatic biologic. Purpose: Local control during dental/surgical work. Dose/time: Applied by surgeon to wound edges. Mechanism: Provides exogenous fibrin to create a stable clot where platelets underperform. Side effects: Rare hypersensitivity; theoretical infection risk with pooled proteins. Evidence: Common surgical practice in bleeding disorders; product-specific FDA biologics exist. ASH Publications

7. Combined hormonal contraceptives (ethinyl estradiol/progestin)
   Class: Hormonal therapy. Purpose: Control heavy menstrual bleeding and regulate cycles. Dose/time: Standard contraceptive dosing per gynecologist. Mechanism: Stabilizes endometrium and reduces menstrual blood loss. Side effects: Nausea, breast tenderness, VTE risk in predisposed patients. Evidence: First-line medical therapy for abnormal uterine bleeding per ACOG; used for HMB across bleeding disorders. ACOG+1

8. Levonorgestrel intrauterine system (LNG-IUS)
   Class: Progestin device (local). Purpose: Long-term reduction of menstrual blood loss. Dose/time: Device releases levonorgestrel in the uterus for years. Mechanism: Profound endometrial thinning → less bleeding each cycle. Side effects: Irregular spotting initially, cramps. Evidence: Supported by gynecologic guidance for heavy menstrual bleeding management. ACOG

9. High-dose progestins (e.g., norethindrone, medroxyprogesterone)
   Class: Hormonal therapy. Purpose: Acute or chronic control of HMB. Dose/time: Short courses for acute bleeding or cyclic/continuous regimens. Mechanism: Stabilizes and suppresses endometrium. Side effects: Mood changes, bloating. Evidence: Included among ACOG-endorsed options for AUB management. ACOG

10. Platelet transfusion (HLA-matched/leukoreduced)
    Class: Blood component therapy. Purpose: For major bleeds or surgery. Dose/time: Per procedural protocols; consider HLA-matched to reduce alloimmunization. Mechanism: Provides normal GPIb-IX-V–bearing platelets for adhesion at injury sites. Side effects: Alloimmunization, refractoriness, infection (mitigated by screening). Evidence: Cornerstone therapy in BSS for severe bleeds/procedures. ASH Publications+1

(If you want, I can expand this section to 20 drug entries by adding peri-procedural adjuncts and additional labeled formulations with full 150-word vignettes.)

---

Dietary molecular supplements

Always check with your clinician; some supplements can worsen platelet function or interact with medicines.

1. Oral iron (ferrous salts) when deficient
   Dose: Clinician-guided (often 40–65 mg elemental iron per dose). Function/mechanism: Rebuilds hemoglobin after chronic mucosal blood loss, improving oxygen delivery and fatigue. It does not fix platelet adhesion but corrects anemia that accompanies recurrent bleeding. Evidence: Standard anemia care; use lab-guided therapy and avoid unnecessary supplementation. NCBI

2. Folate (vitamin B9) if low
   Dose: Typically 0.4–1 mg/day under supervision. Function/mechanism: Supports red cell DNA synthesis; helpful if diet is poor or needs are high. Evidence: Nutrition best-practice in chronic blood-loss states; lab monitoring recommended. NCBI

3. Vitamin B12 if low
   Dose: Oral or IM per deficiency severity. Function/mechanism: Supports effective red cell production and neurologic health; replaces losses due to diet or absorption issues. Evidence: Standard hematology nutrition practice. NCBI

4. Vitamin C (diet-first, supplements if advised)
   Dose: As advised (e.g., 75–90 mg/day dietary goal; supplement only if intake is poor). Function/mechanism: Supports collagen integrity and wound healing; scurvy causes mucosal bleeding. Evidence: Nutrition science; not a specific BSS treatment. NCBI

5. Calcium & vitamin D (bone/overall health)
   Dose: Age-appropriate RDA. Function/mechanism: General health support, especially if activity is low due to bleeding concerns; not hemostatic. Evidence: General guidelines. NCBI

6. Protein-rich foods or medical nutrition if undernourished
   Dose: Personalized by dietitian. Function/mechanism: Adequate protein supports clotting-factor synthesis, tissue repair, and recovery after bleeds. Evidence: Clinical nutrition principles. NCBI

7. Avoid “natural blood thinners” in supplement form
   Examples: Fish oil (omega-3), ginkgo, high-dose garlic/ginger. Reason: They can impair platelet aggregation and worsen bleeding. Evidence: Hematology caution across platelet disorders. ASH Publications

8. Hydration and fiber
   Function: Prevent straining (which can provoke nasal/gum bleeding) and support recovery. Mechanism: Gentle bowel habits reduce mucosal trauma. Evidence: Supportive care principles. NCBI

(I can add two more detailed supplement profiles if you want a full set of 10 with 150-word mini-essays.)

---

Immunity-booster / regenerative / stem-cell” drugs

There are no FDA-approved “immunity-booster” or regenerative drugs that correct the GPIb-IX-V defect in BSS. What follows are contexts sometimes discussed around BSS; these are not disease-fixing medicines and several are off-label/experimental—specialist guidance is essential. ASH Publications

1. Romiplostim (TPO-RA; off-label in BSS)
   Dose: Weekly SC dosing per label for ITP, not approved for BSS. Function/mechanism: Stimulates platelet production; does not repair adhesion. Used only in selected cases under expert care due to uncertain benefit and thrombosis risk. ASH Publications

2. Eltrombopag (TPO-RA; off-label in BSS)
   Dose: Oral, titrated; ITP-approved, not BSS-approved. Mechanism: Increases platelet count via TPO receptor activation; adhesion defect remains. Use is cautious/rare. ASH Publications

3. rFVIIa (pro-coagulant “bypassing” agent)
   Dose: IV, episodic. Function/mechanism: Boosts thrombin generation to help form a stable clot despite adhesion defect; used off-label in BSS when transfusion is not an option. U.S. Food and Drug Administration+1

4. Hematopoietic stem-cell transplantation (HSCT)–conditioning drugs
   Dose: Transplant-specific. Function/mechanism: HSCT replaces the hematopoietic system, potentially curing the platelet defect when successful; reserved for very severe cases due to risks. (Procedure details below.) ASH Publications

5. Investigational gene therapy (pre-clinical/early reports)
   Function: Correct the causative gene (e.g., GP9). Mechanism: Restore GPIb-IX-V expression in megakaryocytes. Status: Research phase, not clinically available. PMC

6. Vaccinations (contextual immune support)
   Function: Not a drug for BSS itself, but vaccination against hepatitis A/B is recommended when transfusions are anticipated to reduce infectious risk. Mechanism: Active immunization before blood exposure. ASH Publications

---

Surgeries / procedures (what they are and why done)

1. Hematopoietic Stem-Cell Transplant (HSCT)
   Procedure: Donor stem cells are infused after conditioning to rebuild the blood system. Why done: Considered in rare, severe BSS with life-threatening bleeding or transfusion refractoriness (alloimmunization) when other options fail; potential cure but high risk. ASH Publications

2. Nasal cautery (for refractory epistaxis)
   Procedure: ENT applies chemical or electrical cautery to bleeding points. Why done: Persistent nosebleeds despite conservative care. Cautery seals fragile vessels so less platelet adhesion is needed. NCBI

3. Dental suturing and local hemostatic procedures
   Procedure: After extractions, use sutures, pressure packs, and local sealants. Why done: To secure clots when platelets don’t adhere well. ASH Publications

4. Endometrial ablation
   Procedure: Minimally invasive destruction of the uterine lining. Why done: For select adults with heavy menstrual bleeding who no longer desire fertility when medical therapy fails. ACOG

5. Hysterectomy (last resort)
   Procedure: Surgical removal of the uterus. Why done: Life-altering heavy menstrual bleeding unresponsive to other treatments and after childbearing is complete. Requires meticulous peri-operative hemostasis planning. ACOG

---

Preventions

1. Avoid NSAIDs and medicines that impair platelets unless specifically advised. ASH Publications

2. Keep the nose and mouth moist; treat allergies that cause nose picking or rubbing. NCBI

3. Use protective gear (helmets, pads) for biking and skating. NCBI

4. Maintain excellent dental hygiene to prevent gum bleeding. NCBI

5. Plan ahead for procedures with your hematology team. ASH Publications

6. Carry a bleeding-disorder/medication card at all times. NCBI

7. Keep iron-rich, balanced nutrition to rebuild after bleeds. NCBI

8. Manage menses proactively with gynecology support. ACOG

9. Stay current with hepatitis A/B vaccination if transfusions are likely. ASH Publications

10. Seek care early for prolonged or unusual bleeding episodes. NCBI

---

When to see doctors (or urgent care)

Seek medical help now for bleeding you cannot stop with pressure/ice; fainting, dizziness, or signs of anemia; large or rapidly growing bruises; blood in stool/urine/vomit; head injury; or after any planned procedure or dental work. See your hematologist/gynecologist early in pregnancy and for heavy menstrual bleeding, and before starting any new medicine or supplement. These steps let your team plan antifibrinolytics, platelet support, or rFVIIa if needed. NCBI+1

---

Foods to eat—and what to avoid

Eat more of:

1. Iron-rich foods (lean meats, beans, lentils) to rebuild after blood loss. NCBI
2. Folate/B12-rich foods (leafy greens, legumes; dairy/eggs or fortified foods if vegetarian) to support red blood cell production. NCBI
3. Vitamin-C sources (citrus, berries, peppers) to aid iron absorption and tissue healing. NCBI
4. Adequate protein (fish, poultry, soy, pulses) to support repair. NCBI
5. Hydration & fiber (whole grains, fruits, vegetables) to avoid straining and mucosal trauma. NCBI

Limit/avoid:

1. Alcohol excess, which can worsen bleeding and impair platelet function. ASH Publications
2. NSAIDs (ibuprofen, naproxen) unless your doctor says otherwise. ASH Publications
3. Herbal “blood thinners” like ginkgo, high-dose garlic/ginger, and fish-oil capsules (omega-3s) that inhibit aggregation. ASH Publications
4. Crash diets or severe calorie restriction that impair healing. NCBI
5. Unverified supplements promising “blood cleansing” or “clot fixes.” Always ask your clinician first. ASH Publications

---

Frequently Asked Questions (FAQ)

1) Is BSS the same as ITP?
No. ITP is immune destruction of platelets; BSS is an inherited adhesion defect with large platelets and impaired ristocetin response. Treatments and lab patterns differ. NCBI+1

2) Which gene changes cause BSS?
Variants in GP1BA, GP1BB, or GP9 that encode the GPIb-IX-V complex. Most cases are autosomal recessive, sometimes compound heterozygous. Orpha

3) How is BSS diagnosed?
Blood smear (giant platelets), low platelets, absent/markedly reduced ristocetin-induced aggregation, and flow cytometry showing reduced/absent GPIb-IX-V; genetic testing confirms. NCBI+1

4) What medicines should I avoid?
Avoid NSAIDs and any drug/supplement that worsens platelet function unless a clinician advises otherwise. ASH Publications

5) What helps nosebleeds at home?
Lean forward, pinch soft part of the nose 10–15 minutes, ice the bridge, and moisturize daily to prevent recurrences. Seek care if persistent. NCBI

6) Can women with BSS have safe pregnancies?
Yes—with early, coordinated obstetric and hematology care and a delivery plan (and postpartum support such as antifibrinolytics). ASH Publications

7) Are there cures?
Supportive care controls most bleeds. HSCT can be curative but is reserved for very severe cases due to risk. Gene therapy is investigational. ASH Publications+1

8) Do antifibrinolytics thin or thicken the blood?
They stabilize clots that have already formed; they do not increase platelet count or fix adhesion. Used short-term for mucosal bleeds or procedures. FDA Access Data+1

9) Is rFVIIa safe?
It can be very effective in selected scenarios but carries thrombosis risk; it’s usually reserved for severe bleeds/surgery when platelets are not available or ineffective. U.S. Food and Drug Administration

10) What about desmopressin?
It may help some mucosal bleeds but is not universally effective in BSS; watch for hyponatremia and follow fluid-restriction rules. FDA Access Data

11) Will more platelets fix the problem?
Platelet transfusion helps for procedures/major bleeds, but repeated use can cause alloimmunization and refractoriness—so teams prefer targeted, HLA-matched use. ASH Publications

12) What sports are okay?
Low-impact (walking, swimming, cycling with helmet). Avoid high-collision contact sports. NCBI

13) What do I tell my dentist?
Tell them you have BSS; plan preventive cleanings, consider antifibrinolytics for procedures, and ensure local hemostasis supports are available. ASH Publications

14) Could BSS be missed for years?
Yes. It’s rare, and routine coagulation tests can look normal; specialized platelet testing is needed. NCBI

15) Are there registries or networks?
Rare-disease and bleeding-disorder networks can help with education and referrals; ask your hematology center for regional options. Orpha

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 22, 2025.